Pricing & Reimbursement for Pharmaceuticals and Medical Devices
Getting the target price reimbursed is of utmost importance to generate desired sales and profit levels. International transparency of national P&R policies is increasing. As a result - price referencing and demand measurements are affecting existing and new prices more than ever. The demonstration of additional medical benefit has become the key driver for P&R. Early benefit assessment has become the key element for innovation classification and price negociation. Clients may suffer from launch delay, reference group classification, price adjustments and planning insecurity. Click here for the PPRI report.
pharmaLevers is helping clients in the following way:
Reimbursement
change payer and decision makers value perception
stakeholder specific value demonstration and argumentation
identify and overcome payer and decision makers value barriers and concerns
adjust core value dossier to the local needs and concerns including value testing
Pricing
argumentation to support pricing claims
P&R policy analysis
innovative pricing solutions
appraisal of price comparison studies
evaluation and assessment of DRG's and codes